TLC590

Approximately 96 million surgical procedures were performed in the United States in 2012. Most surgical patients experience post-surgical pain, but less than half of these patients receive adequate pain relief. This ongoing discomfort has been shown to negatively affect patient outcomes. Ongoing pain can increase recovery time and lead to longer hospital stays and readmissions, thereby increasing non-reimbursed hospital costs.

The current treatment of post-surgical pain may include wound infiltration with local anesthetics combined with the administration of opioid and NSAID analgesics. Opioids are effective but can also cause many undesirable side effects such as sedation, nausea and vomiting, inhibition of bowel function and dependency or addiction, among others. Respiratory depression is a possible life-threatening complication of opioid use.

Bupivacaine and ropivacaine are frequently used for postsurgical pain; however, they suffer from a relatively short half-life. Ropivacaine, the active drug in TLC590, exhibits reduced cardiotoxicity and central nervous system toxicity compared to bupivacaine.

In addition to the existing unmet need of extended release ropivacaine for prolonged pain control, adequate immediate pain control can be elusive, with some physicians co-administering non-liposomal, or immediate release, bupivacaine in addition to liposomal bupivacaine to augment post-operative pain control. 

TLC590 brings sustained release delivery technology to the common anesthetic ropivacaine, with the goal of reducing the frequency of administration for local anesthesia for post-surgical pain. More effective pain relief may also allow patients to avoid the problems of opioid therapies, which are often used for the treatment of post-surgical pain.

tlc_info_img_3.jpg

API

Ropivacaine

DDS Platform

BioSeizer®

Indication

Local anesthesia

Advantages

  • Non-opioid
  • Fast, immediate onset of pain relief
  • Potential pain relief of up to 72 hours
  • Less cardiovascular and central nervous system toxicity
  • Reduced the frequency of administration
  • Proprietary manufacturing process to effectively reduce the cost of production

Development Status

Phase II complete